3.34

4.37% 0.14

After Hours: 3.28 -0.06 -1.80%

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $3.34, with a volume of 1.35M. It is up +4.37% in the last 24 hours and down -4.30% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Previous Close:

$3.20

Open:

$3.21

24h Volume:

1.35M

Relative Volume:

0.87

Market Cap:

$497.93M

Revenue:

$181.41M

Net Income/Loss:

$-59.56M

P/E Ratio:

-7.9524

EPS:

-0.42

Net Cash Flow:

$-38.83M

1W Performance:

+4.37%

1M Performance:

-4.30%

6M Performance:

+41.23%

1Y Performance:

+38.59%

1-Day Range:

$3.21

$3.36

1-Week Range:

$3.145

$3.36

52-Week Range:

$1.69

$3.87

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

377

Twitter

@XerisPharma

Next Earnings Date

2024-12-08

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	3.34	497.93M	181.41M	-59.56M	-38.83M	-0.42
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

Jan 21, 2025

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness - Beloit Daily News

Jan 21, 2025

ADA Partners With Xeris to Combat Rising Diabetes Emergency Cases Amid 202,000 Annual ER Visits - StockTitan

Jan 21, 2025

Jan 16, 2025